Private Trust Co. NA Has $6.20 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Private Trust Co. NA has reduced its holdings in Johnson & Johnson (JNJ) by 3.6%, now owning 40,571 shares valued at approximately $6.20 million.
• Institutional investors hold about 69.55% of Johnson & Johnson's stock, reflecting significant interest from hedge funds.
• Analysts maintain a positive outlook on Johnson & Johnson, with a consensus rating of "Moderate Buy" and a price target of $199.59.

Private Trust Co. NA lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,571 shares of the company's stock after selling 1,499 shares during the period. Johnson & Johnson makes up 0.6% of Private Trust Co. NA's portfolio, making the stock its 23rd biggest position. Private Trust Co. NA's holdings in Johnson & Johnson were worth $6,197,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday, October 10th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. UBS Group raised their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $199.59.

Johnson & Johnson Price Performance

JNJ opened at $193.27 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company's 50 day simple moving average is $180.49 and its 200-day simple moving average is $164.86. The stock has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion for the quarter. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.